Guidance for authorised prescribers of MDMA and psilocybin

To provide guidance to psychiatrists following the Therapeutic Goods Administration’s (TGA) May 2026 recommendations regarding access to 3,4-methylenedioxy-methamphetamine (MDMA) and psilocybin for the purpose of psychedelic-assisted therapy (PAT).